Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer

Increasing numbers of targeted drugs are used in hormone receptor (HR)-positive metastatic breast cancer (MBC) to overcome or delay resistance to endocrine therapy. This study will systemically review the progress made in endocrine therapy combined with targeted therapy in the treatment of HR-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Li, Xu, Feng-Rui, Jiang, Ze-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546887/
https://www.ncbi.nlm.nih.gov/pubmed/32852380
http://dx.doi.org/10.1097/CM9.0000000000000923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546887/
https://www.ncbi.nlm.nih.gov/pubmed/32852380
http://dx.doi.org/10.1097/CM9.0000000000000923

Ejemplares similares